Location of Repository

The Regulation of Human PAI-1 Levels in Blood

By Danny Chung Fan Chan


Plasminogen activator inhibitor type 1 (PAI-1) is the major inhibitor of fibrinolysis.\ud Plasma PAI-1 levels show clear circadian oscillation, peaking in the morning.\ud Expression of the PAI-1 gene may be directly influenced by the –675 4G/5G\ud polymorphism in the PAI-1 promoter. The aim of the present study was to investigate\ud the regulation of PAI-1, using monocytes and platelets as cell models, under conditions\ud that would simulate events occurring within a forming thrombus.\ud Blood from donors genotyped for the 4G/5G polymorphism was used. Direct\ud stimulation of monocyte with lipopolysaccharide (LPS), induced a small increase in\ud Pai-1 expression (710-fold) above baseline, however, monocyte Pai-1 expression was\ud markedly increased (4700-fold) by interaction with platelets activated by cross-linked\ud collagen related peptide (XL-CRP). Furthermore, the induction of monocyte PAI-1\ud expression by platelets was not dependent upon cell-cell contact, but appeared to be\ud mediated by both exogenous and endogenous release of TGF-β1. The induction of\ud monocyte Pai-1 expression by either LPS or CRP-XL was not associated with the\ud 4G/5G polymorphism, but the amount of PAI-1 released into plasma following\ud stimulation was influenced by the polymorphism.\ud Five peripheral clock genes examined were expressed in monocytes under resting\ud conditions. LPS induced the expression of Dec1 and Bmal2 but rapidly switched off the\ud expression of mPer2 and clock in monocytes, whereas the stimulation of monocytes by\ud CRP-XL did not affect the expression of clock genes, apart from the down-regulation of\ud Clock and up-regulation of mPer2. Therefore, the acute induction of PAI-1 in blood\ud cells does not appear to be dependent on the circadian clock.\ud Platelet count significantly increased during the afternoon compared to the morning.\ud But platelet Pai-1 mRNA abundance did not exhibit significant diurnal variation nor\ud was it influenced by the 4G/5G polymorphism. Although anucleate, platelets appear to\ud retain the ability to synthesise PAI-1, which could be partially inhibited by\ud cycloheximide, both the synthesis of PAI-1, and release from α-granules of activated\ud platelets, was related to the 4G/5G polymorphism, with the highest level of PAI-1\ud synthesised and released by platelets from 4G homozygous subjects.\ud In conclusion, PAI-1 in circulatory cells is regulated by circadian factors under resting\ud conditions, but circadian influences may be masked following stimulation. The 4G/5G\ud polymorphism regulates the amount of PAI-1 released by both stimulated monocytes\ud and platelets, and may therefore play a role in the formation or resolution of a thrombus

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/9927

Suggested articles



  1. (2003). 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly,
  2. (2001). 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke in atherothrombotic stroke,
  3. (1999). 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease.
  4. (1984). A clinical evaluation of N-5' with perennial-type allergic-a test by the multipclinic intergroup, double-blind comparative method,
  5. (1994). Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inihibitor-1 in patients with a history of ischemic stroke,
  6. (2001). Activated platelets mediate inflammatory signalling by regulated interlukin 1beta synthesis,
  7. (1996). Activated platelets signal chemokine synthesis by human monocytes,
  8. (2007). Acute systemic inflammation transiently synchronizes clock gene expression in equine peripheral blood,
  9. (1994). ADP causes partial degranulation of platelets in the absence of aggregation,
  10. (1995). Allele specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction,
  11. (2003). Alterations of circadian expression of clock genes in Dahl salt-sensitive rats fed a high salt diet, Hypertension,
  12. (2002). Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization,
  13. (1996). Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin,
  14. (1997). Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men,
  15. (2005). Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells,
  16. (2003). Biochemical importance of glycosylation of plasminogen activator inhibitor-1, Thromb Haemost,
  17. (1985). Biosynthesis of von Willebrand factor by human megakaryocytes,
  18. (1970). Blood fibrinoltyic activity in man. Diurnal variation and the response to varying intensities of exercise,
  19. (1996). Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules,
  20. (2004). Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver,
  21. (2003). Circadian clock genes oscillate in human peripheral blood mononuclear cells,
  22. (1989). Circadian distribution in fatal pulmonary thromboemoblism,
  23. (2007). Circadian expression of clock genes in human peripheral leukocytes,
  24. (2005). Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice,
  25. (2003). Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats,
  26. (1999). Circadian interrelationships among levels of plasma fibrinogen, blood platelets, and serum interleukin-6,
  27. (1996). Circadian occurance of variceal bleeding in patients with liver cirrhosis,
  28. (1997). Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity,
  29. (1985). Circadian variation in the frequency of onset of acute myocardial infarction,
  30. (1991). Circadian variation of fibrinolytic activity in blood,
  31. (1990). Circadian variations
  32. (1999). Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6,
  33. (1991). Circadian variations of platelet aggregability and fibrinolytic activity in healthy subjects,
  34. (1994). Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis, Hepatology,
  35. (1989). Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA using the polymerase chain reaction,
  36. (2002). Cirrhosis does not shift the circadian phase of plasma fibrinolysis,
  37. (2000). CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression,
  38. (2006). CLOCK is involved in obesity-induced disordered fibrinolysis in ob/ob mice by regulating PAI-1 gene expression,
  39. (1987). Compensatory enlargement of human atherosclerotic coronary arteries,
  40. (2004). Coronary heart disease statistics,
  41. (2005). Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity,
  42. (2005). Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder,
  43. (1983). Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells,
  44. (1999). Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation,
  45. (2004). Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells,
  46. (1996). Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor- and lipopolysaccharide,
  47. (2000). Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices,
  48. (1985). Diurnal variation and activity during the onset of strike,
  49. (2003). Editorial comment – genetic make-up for increased PAI-1 expression protects against stroke,
  50. (1998). Effect of activation and inhibition of the rennin-angiotensin system on plasma
  51. (1990). Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (tPA) and tPA/PAI-1 complex in plasma,
  52. (1996). Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential link between obesity and cardiovascular disease,
  53. (1998). elements in the promoter of human plasminogen activator inhibitor-type 1 gene,
  54. (2002). Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type-1 gene,
  55. (1957). Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis,
  56. (2006). Expression of COX-2 in plateletmonocytes interactions occurs via combinatorial regulation involving adhesion and cytokine signalling,
  57. (1989). Expression of MyoD1 coincides with terminal differentiation in determined but inducible muscle cells,
  58. (1998). Fibrinogen plasma levels in an apparently healthy general populationrelation to environmental and genetic determinants,
  59. (1997). Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in
  60. (2004). Functional analysis of the basic helix-loop-helix transciption factor DEC1 in circadian regulation. Interaction with BMAL1,
  61. (2008). Genetic components of the circadian clock regulates thrombogenesis in vivo, Circulation,
  62. (2001). Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction, Circulation,
  63. (1999). Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels,
  64. (1998). High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both mean and women: evidence for the fibrinolytic system as an independent primary risk factor, Circulation,
  65. (1989). Human platelets contain mRNA transcripts for platelet factor 4and actin,
  66. (2004). Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases,
  67. (2001). Hypothalamic integration of central and peripheral clocks,
  68. (2002). Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1,
  69. (2007). Identification of the circadian clock-regulated Ebox element in the mouse plasminogen activator inhibitor-1 gene,
  70. (1985). Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator,
  71. (1999). In cirrhotic patients variceal bleeding is more frequent in the evening and correlates with severity of liver disease,
  72. (1958). In vitro Thrombotic coagulation of the blood. A method for producing a thrombus,
  73. (1985). Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction,
  74. (2005). Induction of PAI-1 expression by
  75. (2004). Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension,
  76. (2006). Inhibition of ALK5 as a new approach to treat liver fibrotic diseases, Drug News Perspect,
  77. (2007). Inhibition of TGF-beta with neutralising antibodies prevents radiation-induced acceleration of metastatic cancer progression,
  78. Inhibitors of the TGF-beta superfamily and their clinical applications,
  79. (1998). Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries, Atherosclerosis,
  80. (2008). Injection of LPS causes transient suppression of biological clock genes in rats,
  81. (1995). Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity,
  82. (1999). Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets,
  83. (2003). Light exposure during daytime modulates expression of Per1 and Per2 clock genes in the suprachiasmatic nuclei of mice,
  84. (1999). Light-independent role of CRY1 and
  85. (1997). Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript,
  86. (2001). Localisation of protein kinase A and vitronectin in resting platelets and their translocation onto fibrin fibers during clot formation,
  87. (1988). Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden death and stroke,
  88. (1999). mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop,
  89. (2007). Mechanisms of microRNA-mediated gene regulation in animal cells, Trends Genet., Vol.23,
  90. (2008). Message in the platelet” – more than just vestigial mRNA! Platelets, Epub ahead of print.
  91. (2006). MicroRNA fingerprint during human megakaryocytopoiesis,
  92. (1994). Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy,
  93. (2001). Molecular analysis of mammalian circadian rhythms,
  94. (2008). Monocyte-mediated defense against microbial pathogens,
  95. (1997). Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex,
  96. (2001). mper1 And mper2 are essential for normal resetting of the circadian clock,
  97. (1983). New synthesis of a platelet-specific protein: Platelet factor 4 synthesis in a megakaryocyte-enriched rabbit bone marrow culture system,
  98. (2005). PAI-1 and atherothrombosis,
  99. (1998). PAI-1 inhibitor enhances the lysis of the platelet-rich part of arterial-like thrombi formed in vitro. A comparative studying using thrombi prepared from rat and human blood,
  100. (1995). Peripheral blood monocyte synthesis of plasminogen activator inhibitor 2 in response to native and modified LDL,
  101. (1996). Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction,
  102. (2000). Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women,
  103. (1987). Plasminogen activator inhibitor in plasma:risk factor for recurrent myocardial infarction,
  104. (1994). Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls,
  105. (2003). Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis,
  106. (2007). Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals,
  107. (2005). Plasminogen activator inhibitor-1 modulates adipocyte differentiation,
  108. (1997). Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography, Arterioscler Thromb Vasc Biol.,
  109. (1994). Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop,
  110. (1988). Plasminogen activator inhibitors--a review,
  111. (1988). Plasminogen activators and their inhibitors,
  112. (1994). Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms,
  113. (2002). Prediction of the risk of myocardial infarction from polymorphisms in candidate genes,
  114. (1997). Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease, Diabetes,
  115. (1967). Protein synthesis by human platelets,
  116. (2004). Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin),
  117. (1998). Recombinant Semliki Forest virus enhanced plasminogen activator inhibitor 1 expression and storage in the megakaryocytic cell line MEG-01,
  118. (2001). Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock,
  119. (1998). Regulation of immune responses by TGF-beta,
  120. (1998). Regulation of plasminogen activator inhibitor-1 mRNA accumulation by basic fibroblast growth factor and transforming growth factor-beta1 in cultured rat astrocytes,
  121. (2003). Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL-1 and BMAL-2,
  122. (1995). Regulation of tranfroming growth factor-beta activation by discrete sequences of thromnospondin-1,
  123. (2005). Relation of the pro-thrombotic state to increasing age (from the Framingham Offspring Study),
  124. (1999). Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss,
  125. Renal injury due to rennin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway,
  126. (2000). Resetting of circadian time in peripheral tissues by glucocorticoid signalling, Science,
  127. (2005). Resetting of peripheral circadian clock by prostaglandin E2,
  128. (2002). Restricted feeding induces daily expression of clock gene and
  129. (1994). Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions, (an injury vessel wall model),
  130. (2001). Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients – Influence of fat distrucbution and insulin-resistance,
  131. (2006). Role of transforming growth factor-beta in the progression of heart failure,
  132. (1993). Roles of a2-antiplasmin and plasminogen activator inhibitor I (PAI-1) in the inhibition of clot lysis,
  133. (2006). Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls,
  134. (1998). Shedding light on the biological clock,
  135. (1998). Signal-dependent translation of a regulatory protein, Bcl-3, in actuvated human platelets,
  136. (1998). Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signalling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter,
  137. (1967). Stable messenger RNA in the synthesis of contractile protein in human platelets,
  138. (1998). Stimulation of plasminogen activator inhibitor-1 expression in immortalized human trophoblast cells cultured under low levels of oxygen,
  139. (2006). The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin,
  140. (1999). The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta,
  141. (1998). The adipocyte and hemostatic balance in obesity.
  142. (1992). The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility,
  143. (1994). The circadian variation in fibrinolytic activity is not related to posture,
  144. (1982). The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation,
  145. (1998). The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells,
  146. (1999). The inetrgrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis,
  147. (2008). The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity, Atherosclerosis,
  148. (2003). The mammalian circadian clock,
  149. (1971). The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes,
  150. (1992). The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts,
  151. (1987). The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells,
  152. (2005). The orhphan nuclear recpetor rev-erbα recruits the NCoR/histone deactylase 3 corepressor to regulate the circadian bmal1 gene,
  153. (2002). The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator,
  154. (2007). The TGF-beta superfamily in cardiovascular biology,
  155. (2006). Therapeutic strategies against TGF-beta signalling pathway in hepatic fibrosis,
  156. (2006). Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions,
  157. (1996). Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice,
  158. (2000). Tissue plasminogen activator, plasminogen activator inhibitor-1 and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke,
  159. (2004). Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes,
  160. (2005). Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta,
  161. (1987). Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts,
  162. (1996). Transforming growth factor-beta: a general review,
  163. (2006). Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma,
  164. (1997). Two period homologs: circadian expression and photic regulation in the suprachiasmatic nuclei,
  165. (1988). Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter,
  166. (1998). Upregulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1,
  167. (1989). Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets,
  168. (1998). Very-low-density lipoprotein response element in the promoter region of the human Plasminogen activator inhibitor –1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia,
  169. (2002). Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.